Personalized inhaled bacteriophage therapy for treatment of multidrug-resistant Pseudomonas aeruginosa in cystic fibrosis

Bacteriophage therapy, a method using lytic viruses as antimicrobials, has been shown to reduce antimicrobial resistance in cystic fibrosis patients. A personalized phage therapy strategy was used, resulting in a significant decrease in sputum Pseudomonas and improved predicted FEV1 levels. The study suggests that this personalized, nebulized phage therapy strategy could potentially impact clinical and microbiologic endpoints, but further research is needed to evaluate its effectiveness in larger clinical trials.